Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effect of a Pleuran-Based Supplement on Salivary IgA Secretion in Children With Recurrent Respiratory Infections

P. Kunc, J. Fabry, M. Matiscakova, K. Istvankova, Z. Diamant, J. Majtan, M. Jesenak

. 2025 ; 102 (-) : 100780. [pub] 20250215

Status not-indexed Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25008415

BACKGROUND: ß-glucans isolated from natural sources have demonstrated pluripotent immunomodulatory potential, making them a promising supportive treatment for the management of recurrent respiratory infections (RRIs) in children. This study aimed to evaluate the effects of a pleuran-based supplement (ß-glucan isolated from Pleurotus ostreatus in combination with vitamin D and zinc) on mucosal immunity -through modulating salivary secretory immunoglobulin A (sIgA) levels -in children with RRIs. METHODS: This monocentric, prospective, open-label pilot study investigated the effect of an orally administered pleuran/vitamin D/zinc supplement (1-2 chewable tablets daily depending on body weight) on the dynamics of sIgA secretion measured in saliva samples collected at three timepoints: at baseline and after 4-6 and 8-10 days. RESULTS: This study included 49 children aged 6-11 years (mean age: 8.2 ± 1.6 years) with a history of one or more of the following conditions in the inclusion criteria: RRIs, allergy, and asthma. After 8-10 days with daily administration of the chewable pleuran/vitamin D/zinc supplement, children exhibited a statistically significant increase in salivary sIgA concentrations compared with baseline (227 ± 211 μg/mL; P = 0.045). No adverse events were observed during the course of the study in relation to the administration of pleuran-based supplement. CONCLUSIONS: We demonstrated the beneficial effects of the short-term administration of a pleuran-based chewable supplement on mucosal immunity through increasing salivatory sIgA levels. This study confirms the favourable safety profile of this pleuran/vitamin D/zinc combination, which could be beneficial for children with acute or recurrent respiratory infections, including children with allergies and/or asthma. Moreover, the significant increases in salivary sIgA concentrations that were observed after a few days of supplementation support the use of pleuran in not only the prevention but also the treatment of acute respiratory infections.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008415
003      
CZ-PrNML
005      
20250422095611.0
007      
ta
008      
250408e20250215xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.curtheres.2025.100780 $2 doi
035    __
$a (PubMed)40160261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kunc, Peter $u Clinic of Paediatric Respiratory Diseases and Tuberculosis, National Institute of Paediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Jessenius Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Teaching Hospital, Martin, Slovakia
245    10
$a Effect of a Pleuran-Based Supplement on Salivary IgA Secretion in Children With Recurrent Respiratory Infections / $c P. Kunc, J. Fabry, M. Matiscakova, K. Istvankova, Z. Diamant, J. Majtan, M. Jesenak
520    9_
$a BACKGROUND: ß-glucans isolated from natural sources have demonstrated pluripotent immunomodulatory potential, making them a promising supportive treatment for the management of recurrent respiratory infections (RRIs) in children. This study aimed to evaluate the effects of a pleuran-based supplement (ß-glucan isolated from Pleurotus ostreatus in combination with vitamin D and zinc) on mucosal immunity -through modulating salivary secretory immunoglobulin A (sIgA) levels -in children with RRIs. METHODS: This monocentric, prospective, open-label pilot study investigated the effect of an orally administered pleuran/vitamin D/zinc supplement (1-2 chewable tablets daily depending on body weight) on the dynamics of sIgA secretion measured in saliva samples collected at three timepoints: at baseline and after 4-6 and 8-10 days. RESULTS: This study included 49 children aged 6-11 years (mean age: 8.2 ± 1.6 years) with a history of one or more of the following conditions in the inclusion criteria: RRIs, allergy, and asthma. After 8-10 days with daily administration of the chewable pleuran/vitamin D/zinc supplement, children exhibited a statistically significant increase in salivary sIgA concentrations compared with baseline (227 ± 211 μg/mL; P = 0.045). No adverse events were observed during the course of the study in relation to the administration of pleuran-based supplement. CONCLUSIONS: We demonstrated the beneficial effects of the short-term administration of a pleuran-based chewable supplement on mucosal immunity through increasing salivatory sIgA levels. This study confirms the favourable safety profile of this pleuran/vitamin D/zinc combination, which could be beneficial for children with acute or recurrent respiratory infections, including children with allergies and/or asthma. Moreover, the significant increases in salivary sIgA concentrations that were observed after a few days of supplementation support the use of pleuran in not only the prevention but also the treatment of acute respiratory infections.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fabry, Jaroslav $u Clinic of Paediatric Respiratory Diseases and Tuberculosis, National Institute of Paediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Jessenius Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
700    1_
$a Matiscakova, Michaela $u Clinic of Paediatric Respiratory Diseases and Tuberculosis, National Institute of Paediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Jessenius Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
700    1_
$a Istvankova, Katarina $u Clinic of Paediatric Respiratory Diseases and Tuberculosis, National Institute of Paediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Jessenius Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
700    1_
$a Diamant, Zuzana $u Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic $u Department of Microbiology, Immunology and Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium
700    1_
$a Majtan, Juraj $u Department of Microbial Genetics, Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia $u Department of Microbiology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia
700    1_
$a Jesenak, Milos $u Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia $u Institute of Clinical Immunology and Medical Genetics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia
773    0_
$w MED00001306 $t Current therapeutic research, clinical and experimental $x 0011-393X $g Roč. 102 (20250215), s. 100780
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40160261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095612 $b ABA008
999    __
$a ok $b bmc $g 2306370 $s 1245490
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 102 $c - $d 100780 $e 20250215 $i 0011-393X $m Current therapeutic research, clinical and experimental $n Curr Ther Res Clin Exp $x MED00001306
LZP    __
$a Pubmed-20250408

Find record

Citation metrics

Archiving options